Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection
- PMID: 1845391
- DOI: 10.1002/eji.1830210603
Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection
Abstract
Healthy, human immunodeficiency virus seronegative (HIV-) volunteers were multiply immunized with a recombinant gp160 (rgp160) candidate acquired immunodeficiency syndrome (AIDS) vaccine. Peripheral blood lymphocytes from volunteers immunized with 40 micrograms or with 80 micrograms (two volunteers per group) of rgp160, as well as from control donors, were tested for T helper (Th) cell function either prior to immunization, 8 to 12 months after the third immunization, or 2 to 5 months after the fourth immunization. The Th cell functional tests included antigen-induced in vitro interleukin 2 (IL 2) production and proliferation in response to influenza A virus (FLU) and to four synthetic peptides of HIV gp120 and gp160, previously demonstrated to be recognized by T cells from HIV naturally infected patients. Our results demonstrate the following: (a) immunization of HIV- individuals with rgp160 results in IL 2 production and T cell proliferation in response to HIV determinants; (b) boosting with rgp160 enhances Th function; (c) HIV-specific Th function is up to 100-fold greater in the multiply immunized volunteers than that observed in asymptomatic, HIV-infected individuals; and (d) multiple immunization with rgp160 does not impair Th function to a non-HIV antigen such as influenza A virus. These results indicate that immunization of uninfected individuals with an HIV subunit vaccine results in much stronger Th cell immunity than does natural infection and suggests that vaccination against HIV may be possible.
Similar articles
-
A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):27-35. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7648281 Clinical Trial.
-
Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.J Clin Invest. 1991 Sep;88(3):876-84. doi: 10.1172/JCI115389. J Clin Invest. 1991. PMID: 1715888 Free PMC article.
-
Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.Nature. 1988 Aug 25;334(6184):706-8. doi: 10.1038/334706a0. Nature. 1988. PMID: 2457809
-
Abnormalities of immune regulation in human immunodeficiency virus infection.Pediatr Res. 1993 Jan;33(1 Suppl):S71-4; discussion S74-5. doi: 10.1203/00006450-199305001-00410. Pediatr Res. 1993. PMID: 8433878 Review.
-
[Immunologic changes associated with human immunodeficiency virus (HIV)].AMB Rev Assoc Med Bras. 1989 May-Jun;35(3):111-6. AMB Rev Assoc Med Bras. 1989. PMID: 2534492 Review. Portuguese.
Cited by
-
Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies.Clin Exp Immunol. 1994 Sep;97(3):361-6. doi: 10.1111/j.1365-2249.1994.tb06095.x. Clin Exp Immunol. 1994. PMID: 7915974 Free PMC article.
-
Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2.Vaccines (Basel). 2020 Jun 10;8(2):293. doi: 10.3390/vaccines8020293. Vaccines (Basel). 2020. PMID: 32531955 Free PMC article.
-
Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.J Clin Invest. 1993 Aug;92(2):919-28. doi: 10.1172/JCI116667. J Clin Invest. 1993. PMID: 7688766 Free PMC article.
-
Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus.J Clin Invest. 1994 Feb;93(2):768-75. doi: 10.1172/JCI117031. J Clin Invest. 1994. PMID: 8113410 Free PMC article.
-
Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro.J Virol. 1995 Apr;69(4):2357-65. doi: 10.1128/JVI.69.4.2357-2365.1995. J Virol. 1995. PMID: 7533857 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical